Low additive effect of hydroxychloroquine on Japanese patients with systemic lupus erythematosus taking calcineurin inhibitor

Hironari Hanaoka, Harunobu Iida, Tomofumi Kiyokawa, Yukiko Takakuwa, Kimito Kawahata

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Aim: To assess for any additive value of hydroxychloroquine (HCQ) in Japanese patients with systemic lupus erythematosus (SLE) depending on calcineurin inhibitors (CNIs). Methods: We retrospectively evaluated patients with SLE who visited our hospital from 2015 to 2016 and were taking prednisolone (PSL) at <20 mg/d and one immunosuppressant (IS). Patients were divided into two groups depending on HCQ use and the groups were compared for changes in SLE Disease Activity Index (SLEDAI), prednisolone (PSL) dose, and cumulative flare rate between patients who were treated and not treated with CNI. Results: Among the 103 patients evaluated, 19 (18.4%) were treated with HCQ. On analysis of all patients, SLEDAI, PSL doses, and cumulative flare rate were significantly reduced in patients who received HCQ compared to those who did not (P = 0.04, P = 0.01, and P = 0.03, respectively). Regarding IS use, we found less additive therapeutic effect in CNI users than in users of other ISs in terms of reduction in SLEDAI and PSL dose (P = 0.05 and P < 0.01, respectively). Conclusions: The addition of HCQ reduced disease activity, PSL dose, and flares in Japanese SLE patients but conferred less additive clinical efficacy when added to CNIs.

Original languageEnglish
Pages (from-to)468-472
Number of pages5
JournalInternational Journal of Rheumatic Diseases
Volume22
Issue number3
DOIs
Publication statusPublished - 2019 Mar 1
Externally publishedYes

Fingerprint

Hydroxychloroquine
Systemic Lupus Erythematosus
Prednisolone
Immunosuppressive Agents
Calcineurin Inhibitors
Therapeutic Uses

Keywords

  • autoimmune diseases
  • calcineurin inhibitors
  • drug combinations
  • hydroxychloroquine
  • systemic lupus erythematosus

ASJC Scopus subject areas

  • Rheumatology

Cite this

Low additive effect of hydroxychloroquine on Japanese patients with systemic lupus erythematosus taking calcineurin inhibitor. / Hanaoka, Hironari; Iida, Harunobu; Kiyokawa, Tomofumi; Takakuwa, Yukiko; Kawahata, Kimito.

In: International Journal of Rheumatic Diseases, Vol. 22, No. 3, 01.03.2019, p. 468-472.

Research output: Contribution to journalArticle

@article{e50eff100c18426c85fb387779127c2e,
title = "Low additive effect of hydroxychloroquine on Japanese patients with systemic lupus erythematosus taking calcineurin inhibitor",
abstract = "Aim: To assess for any additive value of hydroxychloroquine (HCQ) in Japanese patients with systemic lupus erythematosus (SLE) depending on calcineurin inhibitors (CNIs). Methods: We retrospectively evaluated patients with SLE who visited our hospital from 2015 to 2016 and were taking prednisolone (PSL) at <20 mg/d and one immunosuppressant (IS). Patients were divided into two groups depending on HCQ use and the groups were compared for changes in SLE Disease Activity Index (SLEDAI), prednisolone (PSL) dose, and cumulative flare rate between patients who were treated and not treated with CNI. Results: Among the 103 patients evaluated, 19 (18.4{\%}) were treated with HCQ. On analysis of all patients, SLEDAI, PSL doses, and cumulative flare rate were significantly reduced in patients who received HCQ compared to those who did not (P = 0.04, P = 0.01, and P = 0.03, respectively). Regarding IS use, we found less additive therapeutic effect in CNI users than in users of other ISs in terms of reduction in SLEDAI and PSL dose (P = 0.05 and P < 0.01, respectively). Conclusions: The addition of HCQ reduced disease activity, PSL dose, and flares in Japanese SLE patients but conferred less additive clinical efficacy when added to CNIs.",
keywords = "autoimmune diseases, calcineurin inhibitors, drug combinations, hydroxychloroquine, systemic lupus erythematosus",
author = "Hironari Hanaoka and Harunobu Iida and Tomofumi Kiyokawa and Yukiko Takakuwa and Kimito Kawahata",
year = "2019",
month = "3",
day = "1",
doi = "10.1111/1756-185X.13418",
language = "English",
volume = "22",
pages = "468--472",
journal = "International Journal of Rheumatic Diseases",
issn = "1756-1841",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Low additive effect of hydroxychloroquine on Japanese patients with systemic lupus erythematosus taking calcineurin inhibitor

AU - Hanaoka, Hironari

AU - Iida, Harunobu

AU - Kiyokawa, Tomofumi

AU - Takakuwa, Yukiko

AU - Kawahata, Kimito

PY - 2019/3/1

Y1 - 2019/3/1

N2 - Aim: To assess for any additive value of hydroxychloroquine (HCQ) in Japanese patients with systemic lupus erythematosus (SLE) depending on calcineurin inhibitors (CNIs). Methods: We retrospectively evaluated patients with SLE who visited our hospital from 2015 to 2016 and were taking prednisolone (PSL) at <20 mg/d and one immunosuppressant (IS). Patients were divided into two groups depending on HCQ use and the groups were compared for changes in SLE Disease Activity Index (SLEDAI), prednisolone (PSL) dose, and cumulative flare rate between patients who were treated and not treated with CNI. Results: Among the 103 patients evaluated, 19 (18.4%) were treated with HCQ. On analysis of all patients, SLEDAI, PSL doses, and cumulative flare rate were significantly reduced in patients who received HCQ compared to those who did not (P = 0.04, P = 0.01, and P = 0.03, respectively). Regarding IS use, we found less additive therapeutic effect in CNI users than in users of other ISs in terms of reduction in SLEDAI and PSL dose (P = 0.05 and P < 0.01, respectively). Conclusions: The addition of HCQ reduced disease activity, PSL dose, and flares in Japanese SLE patients but conferred less additive clinical efficacy when added to CNIs.

AB - Aim: To assess for any additive value of hydroxychloroquine (HCQ) in Japanese patients with systemic lupus erythematosus (SLE) depending on calcineurin inhibitors (CNIs). Methods: We retrospectively evaluated patients with SLE who visited our hospital from 2015 to 2016 and were taking prednisolone (PSL) at <20 mg/d and one immunosuppressant (IS). Patients were divided into two groups depending on HCQ use and the groups were compared for changes in SLE Disease Activity Index (SLEDAI), prednisolone (PSL) dose, and cumulative flare rate between patients who were treated and not treated with CNI. Results: Among the 103 patients evaluated, 19 (18.4%) were treated with HCQ. On analysis of all patients, SLEDAI, PSL doses, and cumulative flare rate were significantly reduced in patients who received HCQ compared to those who did not (P = 0.04, P = 0.01, and P = 0.03, respectively). Regarding IS use, we found less additive therapeutic effect in CNI users than in users of other ISs in terms of reduction in SLEDAI and PSL dose (P = 0.05 and P < 0.01, respectively). Conclusions: The addition of HCQ reduced disease activity, PSL dose, and flares in Japanese SLE patients but conferred less additive clinical efficacy when added to CNIs.

KW - autoimmune diseases

KW - calcineurin inhibitors

KW - drug combinations

KW - hydroxychloroquine

KW - systemic lupus erythematosus

UR - http://www.scopus.com/inward/record.url?scp=85056149307&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056149307&partnerID=8YFLogxK

U2 - 10.1111/1756-185X.13418

DO - 10.1111/1756-185X.13418

M3 - Article

VL - 22

SP - 468

EP - 472

JO - International Journal of Rheumatic Diseases

JF - International Journal of Rheumatic Diseases

SN - 1756-1841

IS - 3

ER -